Soria, JC
52  results:
Search for persons X
?
2

Safety and clinical activity of the Notch inhibitor, crenig..:

Even, C. ; Lassen, U. ; Merchan, J....
Investigational New Drugs.  38 (2019)  2 - p. 402-409 , 2019
 
?
4

Increasing global accessibility to high-level treatments fo..:

Chargari, C ; Arbyn, M ; Leary, A...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496636/.  , 2022
 
?
6

SARS-CoV-2 vaccination and phase 1 cancer clinical trials:

Yap, TA ; Siu, LL ; Calvo, E...
Yap , TA , Siu , LL , Calvo , E , Lolkema , M , Lorusso , PM , Soria , JC , Plummer , R , de Bono , JS , Tabernero , J & Banerji , U 2021 , ' SARS-CoV-2 vaccination and phase 1 cancer clinical trials ' , The Lancet Oncology , vol. 22 , no. 3 , pp. 298-301 . https://doi.org/10.1016/S1470-2045(21)00017-6.  , 2021
 
?
7

Phase 1 study of the MDM2 inhibitor AMG 232 in patients wit..:

Gluck, WL ; Gounder, MM ; Frank, R...
Gluck , WL , Gounder , MM , Frank , R , Eskens , F , Blay , JY , Cassier , PA , Soria , JC , Chawla , S , de Weger , V , Wagner , AJ , Siegel , D , Vos , F , Rasmussen , E & Henary , HA 2020 , ' Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma ' , Investigational New Drugs , vol. 38 , no. 3 , pp. 831-843 . https://doi.org/10.1007/s10637-019-00840-1.  , 2020
 
?
8

PARP inhibition enhances tumor cell-intrinsic immunity in E..:

Chabanon, RM ; Muirhead, G ; Krastev, DB...
The Journal of clinical investigation, 2019, 129 (3), pp. 1211 - 1228.  , 2020
 
?
9

Beyond DNA repair: the novel immunological potential of PAR..:

Chabanon, RM ; Soria, J-C ; Lord, CJ.
Molecular & cellular oncology, 2019, 6 (2), pp. 1585170 - ?.  , 2019
 
?
10

A phase Ib dose-finding, pharmacokinetic study of the focal..:

Mak, G ; Soria, J-C ; Blagden, SP...
https://discovery.ucl.ac.uk/id/eprint/10074098/1/s41416-019-0452-3.pdf.  , 2019
 
?
11

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Ce..:

Soria, JC ; Ohe, Y ; Vansteenkiste, J...
https://www.nejm.org/doi/pdf/10.1056/NEJMoa1713137?articleTools=true.  , 2019
 
?
13

EPAC-Lung:Pooled analysis of circulating tumor cells in adv..:

Lindsay, C R ; Blackhall, F H ; Carmel, A...
Lindsay , C R , Blackhall , F H , Carmel , A , Gazzaniga , P , Groen , H J M , Krebs , M G , Muinelo-Romay , L , Pantel , K , Rossi , E , Terstappen , L , Wikman , H , Soria , J-C , Farace , F F , Renehan , A , Dive , C , Besse , B & Michiels , S 2019 , ' EPAC-Lung : Pooled analysis of circulating tumor cells in advanced non-small cell lung cancer ' , Annals of Oncology , vol. 30 , no. Suppl 2 , pp. ii7 . https://doi.org/10.1093/annonc/mdz073 ; ISSN:0923-7534.  , 2019
 
?
15

Osimertinib benefit in EGFR-mutant NSCLC patients with T790..:

Remon, J ; Caramella, C ; Jovelet, C...
https://discovery.ucl.ac.uk/id/eprint/1538437/1/mdx017.pdf.  , 2017
 
1-15